Nonmyeloablative Conditioning Does Not Prevent Telomere Shortening after Allogeneic Stem Cell Transplantation

Background. Stem cell transplantation (SCT) may be associated with premature aging of the hematopoietic stem cells. Telomere length reflects the proliferative history of a cell. In most studies published so far on telomere dynamics after myeloablative allogeneic SCT, recipients had shorter telomeres than their respective donors, thus reflecting “accelerated aging” of hematopoietic cells. We evaluated telomere dynamics in patients who underwent transplantation with nonmyeloablative protocols, assuming that the decreased intensity of chemotherapy might prevent telomere attrition. Methods. Telomere length was measured using FISH-FACS method. Telomeres of recipients were compared to their respective donors. Twenty-three consecutive patients after nonmyeloablative SCT were evaluated. A control group consisted of 10 donor-recipient pairs after conventional myeloablative transplantation. Results. There was significant telomere shortening in both recipients of nonmyeloablative and myeloablative conditioning (0.487±0.65 kb, P=0.003; 0.361±0.50 kb, P=0.047 respectively). The extent of telomere shortening in the two groups was not different (P=0.64). There was no correlation between the degree of shortening and parameters such as time interval from transplant, age of donor or recipient, and the number of infused cells. Conclusions. This is the first study on telomere dynamics after nonmyeloablative conditioning SCT. The study demonstrates significant shortening of telomeres in recipients in spite of decreased intensity conditioning. Results of this study suggest that the main mechanism following transplantation is the proliferative stress imposed upon the stem cells and not direct damage by cytotoxic drugs. The different kinetics of restoration of hematopoiesis and the probable ongoing process of graft-versus-leukemia in the bone marrow do not prevent the attrition of telomeric ends of chromosomes.

[1]  A. Smogorzewska,et al.  Regulation of telomerase by telomeric proteins. , 2004, Annual review of biochemistry.

[2]  A. Nagler,et al.  Clinical Implications of Minimal Residual Disease Monitoring for Stem Cell Transplantation after Reduced Intensity and Nonmyeloablative Conditioning , 2004, Acta Haematologica.

[3]  K. Moore,et al.  Stem cells: Interactive niches , 2003, Nature.

[4]  I. Weissman,et al.  Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. , 2003, Blood.

[5]  J. Bourhis,et al.  Therapy‐related myelodysplasia and/or acute myeloid leukaemia after autologous haematopoietic progenitor cell transplantation in a prospective single centre cohort of 221 patients , 2003, British journal of haematology.

[6]  S. Cho,et al.  Telomere length shortening in non-Hodgkin's lymphoma patients undergoing chemotherapy , 2003, Annals of Hematology.

[7]  A. Nagler,et al.  Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity. , 2003, Experimental hematology.

[8]  T. Spitzer The expanding applications of non‐myeloablative stem cell transplantation , 2003, Pediatric transplantation.

[9]  I. Weissman,et al.  Effect of TERT over-expression on the long-term transplantation capacity of hematopoietic stem cells , 2003, Nature Medicine.

[10]  W. Hahn,et al.  Erosion of the telomeric single-strand overhang at replicative senescence , 2003, Nature Genetics.

[11]  R. Storb,et al.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.

[12]  M. Lishner,et al.  Granulocyte colony‐stimulating factor administration upregulates telomerase activity in CD34+ haematopoietic cells and may prevent telomere attrition after chemotherapy , 2003, British journal of haematology.

[13]  P. Lansdorp,et al.  Telomere shortening in hematopoietic stem cell transplantation: a potential mechanism for late graft failure? , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  R. DePinho,et al.  Connecting chromosomes, crisis, and cancer. , 2002, Science.

[15]  John Doyle,et al.  Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss. , 2002, Blood.

[16]  J. Campisi,et al.  Telomeres, aging and cancer: In search of a happy ending , 2002, Oncogene.

[17]  S. Ackland,et al.  Telomere Length in Haemopoietic Stem Cells can be Determined from that of Mononuclear Blood Cells or Whole Blood , 2002, Leukemia & lymphoma.

[18]  A. Multani,et al.  Human bone marrow transplant rejection is associated with telomere cleavage. , 2001, International journal of molecular medicine.

[19]  S. Shin,et al.  Different onsets of oxidative damage to DNA and lipids in bone marrow and liver in rats given total body irradiation. , 2001, Free radical biology & medicine.

[20]  R. Cancedda,et al.  High‐dose chemotherapy shows a dose‐dependent toxicity to bone marrow osteoprogenitors , 2001, Cancer.

[21]  Margaret A. Strong,et al.  The Shortest Telomere, Not Average Telomere Length, Is Critical for Cell Viability and Chromosome Stability , 2001, Cell.

[22]  R. Nowak,et al.  Wiedemann-Rautenstrauch (neonatal progeroid) syndrome: new case with normal telomere length in skin fibroblasts. , 2001, American journal of medical genetics.

[23]  A. Jauch,et al.  Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas , 2001, Oncogene.

[24]  T. Brümmendorf,et al.  Limited Telomere Shortening in Hematopoietic Stem Cells after Transplantation , 2001, Annals of the New York Academy of Sciences.

[25]  N. Russell,et al.  Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant , 2001, Bone Marrow Transplantation.

[26]  G. Wisman,et al.  Human Telomere Length in Breast Cancer Patients before and after Chemotherapy with or without Stem Cell Transplantation , 2000 .

[27]  I. Weissman,et al.  Telomere Shortening Accompanies Increased Cell Cycle Activity during Serial Transplantation of Hematopoietic Stem Cells , 2001, The Journal of experimental medicine.

[28]  R. Cancedda,et al.  Bone Marrow Stromal Damage after Chemo/Radiotherapy: Occurrence, Consequences and Possibilities of Treatment , 2001, Leukemia & lymphoma.

[29]  T. Brümmendorf,et al.  Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipients. , 2000, Blood.

[30]  P. Mcgale,et al.  Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. , 2000, Blood.

[31]  M. Urashima,et al.  Shortening of telomeres in recipients of both autologous and allogeneic hematopoietic stem cell transplantation , 2000, Bone Marrow Transplantation.

[32]  M. Freedman,et al.  Telomere shortening in leucocyte subsets of long‐term survivors of allogeneic bone marrow transplantation , 1999, British journal of haematology.

[33]  Lynda Chin,et al.  E.: “A Summary of , 1968 .

[34]  K. Ohyashiki,et al.  Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  R. Effros Replicative senescence in the immune system: impact of the Hayflick limit on T-cell function in the elderly. , 1998, American journal of human genetics.

[36]  J. Shay Accelerated telomere shortening in bonemarrow recipients , 1998, The Lancet.

[37]  T. Dexter,et al.  Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants , 1998, The Lancet.

[38]  A. Cimmino,et al.  In vivo telomere dynamics of human hematopoietic stem cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  B L Levine,et al.  Human naive and memory T lymphocytes differ in telomeric length and replicative potential. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E. Rogaev,et al.  Telomere shortening is associated with cell division in vitro and in vivo. , 1995, Experimental cell research.

[41]  C B Harley,et al.  Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[42]  H. Deeg,et al.  Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. , 1989, The New England journal of medicine.

[43]  J. Abrams,et al.  Increased exhaled nitric oxide following autologous peripheral hematopoietic stem-cell transplantation: a potential marker of idiopathic pneumonia syndrome. , 2004, Chest.

[44]  D. Broccoli,et al.  Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients , 2004, Bone Marrow Transplantation.

[45]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience. , 2004, Current hematology reports.

[46]  H. Tanke,et al.  Homeostasis of telomere length rather than telomere shortening after allogeneic peripheral blood stem cell transplantation. , 2003, Blood.

[47]  T. von Zglinicki Oxidative stress shortens telomeres. , 2002, Trends in biochemical sciences.

[48]  Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the Duet™ (BioView) combined morphological and cytogenetical analysis , 2002, Leukemia.

[49]  R. Childs,et al.  Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy. , 2002, Seminars in hematology.

[50]  A. Nagler,et al.  Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet™) combined morphological and cytogenetical analysis , 2002, Leukemia.

[51]  A. Nagler,et al.  Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations , 2001, Leukemia.

[52]  D. Blaise,et al.  Allogeneic peripheral blood stem cell transplantation results in less alteration of early T cell compartment homeostasis than bone marrow transplantation , 2001, Bone Marrow Transplantation.

[53]  P. Lansdorp,et al.  Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry , 1998, Nature Biotechnology.

[54]  M. Engelhardt,et al.  Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy , 1998, Leukemia.

[55]  Wei Han,et al.  Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. , 1997, Blood.